Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07732491) titled 'Culmerciclib in HR+/HER2+ Advanced Breast Cancer' on July 23.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sun Yat-sen University
Condition:
Breast Cancer
Metastastic Breast Cancer
HER2+ Advanced Breast Cancer
Intervention:
Drug: Culmerciclib
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: August 1, 2026
Target Sample Size: 35
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07732491
Disclaimer: Curated by HT S...